Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease

BMJ Open

Volumn 3, Issue 7, 2013, Pages

  Alrubaiy, L ^a   Hutchings, H A ^a   Williams, J G ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

ADULT; ARTICLE; CCQ QUESTIONNAIRE; CISS SCORE; CLINICAL ASSESSMENT TOOL; CLINICAL PROTOCOL; COHORT ANALYSIS; CONSTRUCT VALIDITY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MEDICAL RESEARCH; MEDICAL SPECIALIST; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; POINT OF CARE TESTING; PROSPECTIVE STUDY; PSYCHOMETRY; QUALITY OF LIFE INDEX; QUESTIONNAIRE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SHORT FORM 12; TEST RETEST RELIABILITY; ULCERATIVE COLITIS;

EID: 84880635627     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003192     Document Type: Article

References (37)

1. National Association for Colitis and Crohn's Disease. Inflammatory bowel disease basics. http://www.nacc.org.uk/content/ibd.asp (accessed 20 Oct. 2010).
2. IBD Standards Group. Quality care. Service standards for the healthcare of people who have Inflammatory Bowel Disease (IBD). 2009. http://www. ibdstandards.org.uk/ (accessed 12 May 2009).
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
5. Ferkolj I. How to improve the safety of biologic therapy in Crohn's disease. J Physiol Pharmacol 2009;60(Suppl 7):67-70.
6. National Institute for Health and Clinical Excellence. Crohn's disease-Infliximab (review) and Adalimumab, TA187 (review of TA40). London. 2010.
7. Irvine EJ. Health related quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008;14:554-65. (Pubitemid 351571837)
8. Mitchell A, Guyatt G, Singer J, et al. Health related quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306-10.
9. Cheung WY, Garratt AM, Russell IT, et al. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire. Development and validation. J Clin Epidemiol 2000;53:297-306. (Pubitemid 30173250)
10. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of severity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
11. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of severity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30. (Pubitemid 34117002)
12. Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:438-44.
13. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415-22.
14. Marx RG, Bombardier C, Hogg-Johnson S, et al. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999;52:105-11. (Pubitemid 29118359)
15. Streiner DL, Norman GR. Health measurement scales. A practical guided to their development uses. 4th edn. OUP, 2008.
16. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. (Pubitemid 126433231)
17. EuroQoL Group. EuroQoL: a new facility for the measurement of heath-related quality of life. Health Policy 1990;16:199-208.
18. Barrett P, Kline P. The observation to variable ratio in factor analysis. J Personality Group Behaviour 1981;1:23-33.
19. Nunnally JC. Psychometric theory. New York: McGraw-Hill, 1978.
20. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514.
21. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998;43:29-32. (Pubitemid 28335486)
22. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32.
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
24. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6. (Pubitemid 19032930)
25. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12. (Pubitemid 39311530)
26. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955;2:1041-8.
27. Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-7. (Pubitemid 12120288)
28. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16-19. (Pubitemid 20207870)
29. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188-97. (Pubitemid 23219711)
30. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-407. (Pubitemid 34664784)
31. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507. (Pubitemid 41007865)
32. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971-6.
33. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
34. Van Hees PA, Van Elteren PH, Van Lier HJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980;21:279-86. (Pubitemid 10056059)
35. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity-the Cape Town index. S Afr Med J 1985;68:502-3. (Pubitemid 16198618)
36. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405. (Pubitemid 29205403)
37. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002;137:774-7. (Pubitemid 34743162)